Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assess Hemay808 Concentration of Different Dosage Regimen for Mild and Moderate Atopic Dermatitis Patients the Safety and Efficacy of Multicenter, Randomized, Blinded, Excipient Parallel-group Phase Ⅱ Clinical Study

NCT04352595 is registered in ClinicalTrials.gov with Tianjin Hemay Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT04352595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04352595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assess Hemay808 Concentration of Different Dosage Regimen for Mild and Moderate Atopic Dermatitis Patients the Safety and Efficacy of Multicenter, Randomized, Blinded, Excipient Parallel-group Phase Ⅱ Clinical Study
Lead sponsor
Tianjin Hemay Pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
April 24, 2020
Completion date
April 2, 2021
Enrollment
148 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis